Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 53.50
+0.25 (0.47%)
Jul 30, 2026, 3:35 PM HKT
Shanghai Henlius Biotech Earnings Call Transcripts
Fiscal Year 2026
-
The session highlighted a robust global pipeline with multiple late-stage assets, strong clinical data in oncology, and ambitious expansion plans. Key milestones include upcoming regulatory filings, pivotal trial launches, and a focus on next-gen immuno-oncology and ADCs.